Publications
| 2008-07-17 |
Breakthrough Vaccine - Monkeys are completely protected against Dengue Fever by GenPhar's tetravalent Dengue Virus vaccine. |
| A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol. 2008 Jul;82(14):6927-34. Epub 2008 May 14. |
| More than 100 million Dengue Fever infections occur each year and a dengue viruses vaccine has become a global health priority - GenPhar has now developed a safe and effective vaccine against all four Dengue virus serotypes. GenPhar has been working in close collaboration with the US Naval Medical Research Center. The CAdVax based vaccine induces rapid and sustained protective immune responses in monkeys against two separate live-virus challenges. These results demonstrate that the tetravalent dengue vaccine formulation provides significant protection in rhesus macaques against challenge with all four dengue virus serotypes. Click here for full pdf from Journal of Virology website |
| About GenPhar, Inc. GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world’s most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina. To learn more about GenPhar and its vaccine programs, please contact us. |
print this page
contact us
site map